The new patent covers several new quinoxalinyl-piperazine compounds, the process for their preparation, pharmaceutical composition, and a method for their producing an anti-proliferative effect.
Additionally, the new patent also covers the company’s pre-clinical compound RX-5902, which is currently being developed by the company and human trials are expected to start this year.
Rexahn Pharma president Rick Soni the issuance of this patent will enhance the commercial potential of RX-5902 in Europe .